Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00129467 · ClinicalTrials.gov registry record · NA

Methylphenidate for Depressed Cancer Patients Receiving Palliative Care

A NA study, sponsored by US Department of Veterans Affairs.

Completed
Registry status
NA
Development phase
47
Enrollment target

NCT00129467 is a NA study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 47 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00129467, a NA study, has completed, sponsored by US Department of Veterans Affairs.

COMPLETED
Registry status
NA
Development phase
47 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care cancer patients. The investigators hypothesize that depressed hospice and palliative care patients will be more likely to have a 50% reduction in scores on a clinical measure of depression after treatment with Methylphenidate plus an SSRI compared to those patients who are taking a placebo plus an SSRI.

Interventions

  • DRUG Placebo
  • DRUG Methylphenidate
  • DRUG Selective Serotonin Uptake Inhibitor (SSRI)

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2005-02
Est. Completion 2010-12
Phase NA

Sponsor

US Department of Veterans Affairs

632 total trials

What the Registry Record Tells You About NCT00129467

The ClinicalTrials.gov registry entry for NCT00129467 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Department of Veterans Affairs, which has 632 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT00129467 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00129467 about?

NCT00129467 is a clinical study titled "Methylphenidate for Depressed Cancer Patients Receiving Palliative Care". The purpose of this study is to determine whether methylphenidate is an effective treatment for depression and to document the safety and tolerability of methylphenidate in combination with an Selective Serotonin Reuptake Inhibitor (SSRI) in SSRI treated, terminally ill, hospice and palliative care ...

What is the current status of trial NCT00129467?

This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2005-02. Estimated completion is 2010-12.

What interventions are being tested in trial NCT00129467?

The interventions under investigation include: Placebo (DRUG), Methylphenidate (DRUG), Selective Serotonin Uptake Inhibitor (SSRI) (DRUG).

Who is sponsoring clinical trial NCT00129467?

This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.